The addition of an anti-CD54 mAb to elotuzumab and elotuzumab plus lenalidomide-treated cultures also significantly decreased myeloma cell killing, although to a lesser extent than that obtained by blocking with anti-CD18 mAb (Fig. 3a). This evidence concerns the gene ICAM1 and plasma cell myeloma.